Inspection successfully concluded
In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules. Upon the successful inspection the competent national authority granted LTS the extension of its current manufacturer’s authorisation according to §13 AMG to include the manufacturing of capsules. LTS passed a significant milestone towards the marketing of a new innovative drug delivery system allowing for example the combination of oral thin films with capsules.
LTS Lohmann Therapy-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.
Dr. Iris Schnitzler, E-Mail: firstname.lastname@example.org